| Dr Bonnie Simon Grossman, MD | |
|
14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 | |
| (803) 434-6771 | |
| Not Available |
| Full Name | Dr Bonnie Simon Grossman |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 13 Years |
| Location | 14 Richland Medical Park Dr Ste 320, Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427345479 | NPI | - | NPPES |
| 338469 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 33846 (South Carolina) | Primary |
| 207Q00000X | Family Medicine | 33846 (South Carolina) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prisma Health Richland Hospital | Columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prisma Health Medical Group-midlands | 5991099707 | 865 |
News Archive
Fight for Sight is encouraging applicants to apply for the Project Grants Awards. The call for the £250k award to undertake a three year project, is now open.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.
The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.
› Verified 1 days ago
| Entity Name | Carolinas Medical Alliance Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023238490 PECOS PAC ID: 9739096769 Enrollment ID: O20050201000341 |
News Archive
Fight for Sight is encouraging applicants to apply for the Project Grants Awards. The call for the £250k award to undertake a three year project, is now open.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.
The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.
› Verified 1 days ago
| Entity Name | Hospital Physician Services - Southeast Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410385 PECOS PAC ID: 5597774554 Enrollment ID: O20100107000067 |
News Archive
Fight for Sight is encouraging applicants to apply for the Project Grants Awards. The call for the £250k award to undertake a three year project, is now open.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.
The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.
› Verified 1 days ago
| Entity Name | Sound Physicians Of South Carolina, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922428358 PECOS PAC ID: 6800014762 Enrollment ID: O20140905002528 |
News Archive
Fight for Sight is encouraging applicants to apply for the Project Grants Awards. The call for the £250k award to undertake a three year project, is now open.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.
The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.
› Verified 1 days ago
| Entity Name | Cogent Healthcare Of Georgia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609827823 PECOS PAC ID: 2961483607 Enrollment ID: O20151015001850 |
News Archive
Fight for Sight is encouraging applicants to apply for the Project Grants Awards. The call for the £250k award to undertake a three year project, is now open.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.
The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.
› Verified 1 days ago
| Entity Name | Prisma Health Medical Group-midlands |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275988321 PECOS PAC ID: 5991099707 Enrollment ID: O20160802001226 |
News Archive
Fight for Sight is encouraging applicants to apply for the Project Grants Awards. The call for the £250k award to undertake a three year project, is now open.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.
The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bonnie Simon Grossman, MD Po Box 743904, Atlanta, GA 30374-3904 Ph: (803) 296-7320 | Dr Bonnie Simon Grossman, MD 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Ph: (803) 434-6771 |
News Archive
Fight for Sight is encouraging applicants to apply for the Project Grants Awards. The call for the £250k award to undertake a three year project, is now open.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells. Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's immune system is too active.
The cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in "Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation" by Khan, et al.
› Verified 1 days ago
Keith Reeves Barron Jr., MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 14 Richland Medical Park Dr, Suite 320, Columbia, SC 29203 Phone: 803-434-6771 Fax: 803-434-3955 | |
Yohannes Negash, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Sc House Calls Inc, 111 Doctors Circle, Columbia, SC 29203 Phone: 800-491-0909 Fax: 803-434-3955 | |
Dr. Bret Michael James Clawson, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Phone: 803-434-6771 Fax: 803-434-3955 | |
Dr. Ogheneruona Osehi Odili, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Richland Medical Park Dr Ste 420, Columbia, SC 29203 Phone: 803-434-6430 Fax: 803-545-5353 | |
Dr. David Porter Heintze Jr., MD Hospitalist Medicare: Medicare Enrolled Practice Location: 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Phone: 803-434-6771 Fax: 803-434-3955 | |
Brian Kluge, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 14 Richland Medical Park Dr Ste 320, Columbia, SC 29203 Phone: 803-434-6771 Fax: 803-434-3955 | |
Dr. Marcus Owen Vaught, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Taylor At Marion, Columbia, SC 29220 Phone: 803-296-5579 Fax: 803-434-1537 |